Northwest Quadrant Wealth Management LLC Invests $209,000 in AstraZeneca PLC $AZN

Northwest Quadrant Wealth Management LLC purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 2,726 shares of the company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Diversify Wealth Management LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $234,000. Xponance Inc. lifted its stake in shares of AstraZeneca by 18.5% during the 3rd quarter. Xponance Inc. now owns 4,189 shares of the company’s stock worth $321,000 after acquiring an additional 654 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in shares of AstraZeneca by 30.8% during the 3rd quarter. Integrated Advisors Network LLC now owns 5,434 shares of the company’s stock worth $417,000 after acquiring an additional 1,281 shares during the last quarter. Hohimer Wealth Management LLC boosted its holdings in AstraZeneca by 7.1% during the 3rd quarter. Hohimer Wealth Management LLC now owns 21,038 shares of the company’s stock valued at $1,614,000 after acquiring an additional 1,387 shares during the period. Finally, Choreo LLC grew its position in AstraZeneca by 4.9% in the 3rd quarter. Choreo LLC now owns 47,079 shares of the company’s stock valued at $3,612,000 after acquiring an additional 2,178 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AZN shares. Morgan Stanley reiterated an “overweight” rating and set a $103.00 target price on shares of AstraZeneca in a research report on Wednesday, December 3rd. Wall Street Zen downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Citigroup started coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Stock Down 1.1%

Shares of AZN stock opened at $203.56 on Friday. AstraZeneca PLC has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The firm has a market capitalization of $315.70 billion, a PE ratio of 67.63, a P/E/G ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The stock’s 50-day simple moving average is $133.56 and its 200-day simple moving average is $101.08.

AstraZeneca Dividend Announcement

The firm also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s dividend payout ratio (DPR) is currently 74.83%.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.